Internal Medicine, Hematology & Oncology · Sacramento, CA
NPI
1619132461
Since 2008
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
2279 45th Street
Sacramento, CA, 95817
Phone (916) 734-5959
Groups this clinician bills Medicare through
Medicare paid, 2024
$38K
676 services
Medicare patients, 2024
169
Average age 72
Drug cost, 2024
$3.6M
565 prescriptions
Company payments, 2025
$46K
From 16 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Jonathan W Riess was code G2211 (visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's), 233 times for 111 patients. In total Jonathan W Riess billed 676 services in 19 codes, and Medicare paid $38K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2019-09-05.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|---|---|---|---|---|
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 233 | 111 | $13.41 | $3,124 |
| 99214 Office E&M - Established | Facility | 218 | 100 | $77.97 | $17K |
| 99215 Office E&M - Established | Facility | 51 | 40 | $110.55 | $5,638 |
| 99213 Office E&M - Established | Facility | 43 | 35 | $51.99 | $2,236 |
| 99232 Hospital E&M - Subsequent | Facility | 27 | 17 | $63.16 | $1,705 |
| 99205 Office E&M - New | Facility | 18 | 18 | $137.29 | $2,471 |
| 99442 Telephone Services | Facility | 16 | 13 | $49.91 | $798 |
| 99222 Hospital E&M - Initial | Facility | 11 | 11 | $103.95 | $1,143 |
By year: 2022 $40K for 489 services; 2023 $45K for 569 services; 2024 $38K for 676 services.
Medicare prescription drug claims, 2024
In 2024, the drug Jonathan W Riess prescribed most often to Medicare patients was Tagrisso (Osimertinib Mesylate), with 105 prescriptions and refills. In total Jonathan W Riess wrote 565 Medicare prescriptions that cost $3.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Tagrisso Osimertinib Mesylate | 105 | 105 | 14 | $1.7M |
| Alecensa Alectinib Hcl | 53 | 53 | Under 11 | $1.0M |
| Dexamethasone Generic | 47 | 47 | 25 | $262 |
| Prochlorperazine Maleate Generic | 42 | 42 | 24 | $526 |
| Ondansetron Hcl Generic | 35 | 35 | 20 | $178 |
| Erlotinib Hcl Generic | 30 | 30 | Under 11 | $11K |
| Retevmo Selpercatinib | 27 | 27 | Under 11 | $389K |
| Olanzapine Generic | 18 | 18 | 11 | $15.75 |
| Xarelto Rivaroxaban | 14 | 14 | Under 11 | $7,739 |
| Xalkori Crizotinib | 11 | 11 | Under 11 | $186K |
| Mirtazapine Generic | 11 | 11 | Under 11 | $379 |
Brand drugs: - claims; generic drugs: 302 claims; opioid claims: 12.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Jonathan W Riess $46K ($34K in general payments such as food, travel and fees and $12K for research) from 16 companies. The largest payer was GlaxoSmithKline, LLC. with $15K.
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. GSK | 17 | $15K |
| Taiho Oncology, Inc. 4578.T | 8 | $6,594 |
| AstraZeneca Pharmaceuticals LP AZN | 13 | $6,261 |
| Eli Lilly and Company LLY | 2 | $5,200 |
| Pfizer Inc. PFE | 6 | $4,108 |
| E.R. Squibb & Sons, L.L.C. BMY | 1 | $3,820 |
| Janssen Biotech, Inc. JNJ | 3 | $3,432 |
| Janssen Scientific Affairs, LLC JNJ | 2 | $1,383 |
| Regeneron Healthcare Solutions, Inc. REGN | 4 | $182 |
| Mirati Therapeutics, Inc. BMY | 2 | $165 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.